Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

1.3K
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
1.3K
Cushing Syndrome I: Introduction01:26

Cushing Syndrome I: Introduction

67
Cushing syndrome refers to the collection of clinical manifestations that arise when tissues are exposed to excessive amounts of cortisol or cortisol-like medications over an extended period. Cortisol, a glucocorticoid produced by the adrenal cortex, regulates metabolism, immune responses, and the body’s adaptation to stress. When its concentration remains chronically elevated, these physiological pathways become dysregulated, resulting in the characteristic features of the...
67
Cushing Syndrome II: Pathophysiology01:19

Cushing Syndrome II: Pathophysiology

58
Cortisol production is normally governed by the hypothalamic–pituitary–adrenal (HPA) axis, which maintains hormonal balance through tightly regulated feedback mechanisms. Disruption of this regulatory system is central to the development of Cushing syndrome, whether the excess cortisol originates from external medications or internal pathology. Persistent cortisol elevation alters metabolism, immune function, and endocrine signaling, producing the characteristic clinical features...
58
Alzheimer Disease l: Introduction01:29

Alzheimer Disease l: Introduction

38
Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...
38
Alzheimer Disease ll: Pathophysiology01:23

Alzheimer Disease ll: Pathophysiology

44
Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and...
44
Huntington Disease l: Introduction01:21

Huntington Disease l: Introduction

166
Huntington disease or HD is a progressive, fatal neurodegenerative disorder inherited in an autosomal dominant pattern.PathophysiologyIt is caused by expansion of the CAG trinucleotide repeat in the HTT gene on chromosome 4 (4p16.3), producing an abnormal huntingtin protein with an expanded polyglutamine tract. This misfolded protein disrupts cellular function, leading to neuronal death. Normal alleles have ≤26 repeats, 27–35 are intermediate (risk of expansion), 36–39 show...
166

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Comparative diagnostic performance of ACR 1997, SLICC 2012, and EULAR/ACR 2019 criteria in childhood-onset systemic lupus erythematosus: A retrospective study from a tertiary care centre in south India.

Rheumatology and immunology research·2026
Same author

Massive haemoptysis secondary to pulmonary artery aneurysms in Hughes-Stovin syndrome: a variant of Behçet's disease managed with immunosuppression and endovascular embolisation.

BMJ case reports·2026
Same author

Response to Commentary.

Mediterranean journal of rheumatology·2026
Same author

On proline isomerization and 3D-domain-swapping.

Biochemical and biophysical research communications·2026
Same author

Diffuse alveolar hemorrhage in rheumatic diseases: Clinical features, diagnosis, and management.

Rheumatology and immunology research·2026
Same author

Dual‑Energy CT in Inflammatory Arthritis: A Comprehensive Review.

Cureus·2026

Related Experiment Video

Updated: May 6, 2026

Use of Electromagnetic Navigational Transthoracic Needle Aspiration E-TTNA for Sampling of Lung Nodules
06:03

Use of Electromagnetic Navigational Transthoracic Needle Aspiration E-TTNA for Sampling of Lung Nodules

Published on: May 23, 2015

22.2K

Methotrexate-Induced Accelerated Nodulosis: A Case Series.

Ramaswamy Subramanian1, Nikita Chettri2, Rahul Bisaralli3

  • 1Department of Clinical Immunology and Rheumatology, JSS Medical College, JSS Academy of Higher Education and Research, Mysuru, India.

Mediterranean Journal of Rheumatology
|January 31, 2025
PubMed
Summary

Methotrexate-induced accelerated nodulosis (MIAN) is a rare side effect of methotrexate therapy for autoimmune diseases. This case series aims to improve recognition, diagnosis, and management of MIAN to reduce patient burden.

Keywords:
human leukocyte antigenhydroxychloroquinerheumatoid arthritissubcutaneous nodulessulfasalazine

More Related Videos

Using Micro-computed Tomography for the Assessment of Tumor Development and Follow-up of Response to Treatment in a Mouse Model of Lung Cancer
11:31

Using Micro-computed Tomography for the Assessment of Tumor Development and Follow-up of Response to Treatment in a Mouse Model of Lung Cancer

Published on: May 20, 2016

10.6K
Establishment and Characterization of Patient-Derived Xenograft Models of Anaplastic Thyroid Carcinoma and Head and Neck Squamous Cell Carcinoma
06:08

Establishment and Characterization of Patient-Derived Xenograft Models of Anaplastic Thyroid Carcinoma and Head and Neck Squamous Cell Carcinoma

Published on: June 2, 2023

1.7K

Related Experiment Videos

Last Updated: May 6, 2026

Use of Electromagnetic Navigational Transthoracic Needle Aspiration E-TTNA for Sampling of Lung Nodules
06:03

Use of Electromagnetic Navigational Transthoracic Needle Aspiration E-TTNA for Sampling of Lung Nodules

Published on: May 23, 2015

22.2K
Using Micro-computed Tomography for the Assessment of Tumor Development and Follow-up of Response to Treatment in a Mouse Model of Lung Cancer
11:31

Using Micro-computed Tomography for the Assessment of Tumor Development and Follow-up of Response to Treatment in a Mouse Model of Lung Cancer

Published on: May 20, 2016

10.6K
Establishment and Characterization of Patient-Derived Xenograft Models of Anaplastic Thyroid Carcinoma and Head and Neck Squamous Cell Carcinoma
06:08

Establishment and Characterization of Patient-Derived Xenograft Models of Anaplastic Thyroid Carcinoma and Head and Neck Squamous Cell Carcinoma

Published on: June 2, 2023

1.7K

Area of Science:

  • Rheumatology
  • Dermatology
  • Immunology

Background:

  • Methotrexate (MTX) is a widely used disease-modifying antirheumatic drug (DMARD) for various autoimmune conditions.
  • Methotrexate-induced accelerated nodulosis (MIAN) is an uncommon adverse effect associated with MTX treatment.
  • MIAN can cause significant morbidity and impact treatment adherence in patients with autoimmune diseases.

Purpose of the Study:

  • To describe the clinical characteristics, diagnostic methods, and management of patients experiencing MIAN.
  • To enhance the medical community's awareness of this rare MTX side effect.
  • To provide insights for earlier diagnosis and improved clinical strategies for MIAN.

Main Methods:

  • A case series approach was employed.
  • Patients diagnosed with MIAN were retrospectively reviewed.
  • Clinical data, including presentation, diagnosis, and treatment outcomes, were analyzed.

Main Results:

  • The study presents a series of patients with MIAN, detailing their specific clinical presentations.
  • Diagnostic challenges and successful management strategies are discussed based on the cases.
  • The findings highlight the variability in MIAN presentation and response to interventions.

Conclusions:

  • Increased recognition of MIAN is crucial for timely diagnosis and intervention.
  • Effective management strategies can mitigate the impact of this rare MTX complication.
  • This case series contributes to understanding and managing methotrexate-induced accelerated nodulosis.